August 2025 in “Scientific Reports” C4BPA protein may link acne severity and insulin resistance.
1 citations
,
November 2020 in “International Journal of Dermatology” Methotrexate caused a rare skin rash in a rheumatoid arthritis patient, which resolved after stopping the drug.
3 citations
,
July 2025 in “Clinical and Experimental Dermatology” Ritlecitinib may be more effective for severe alopecia areata than conventional treatments.
New drugs, baricitinib and ritlecitinib, are effective for severe alopecia areata.
1 citations
,
January 2018 in “Cogent Medicine” Careful management of steroid use is crucial in pregnant women with bullous pemphigoid to avoid complications like Cushing syndrome.
30 citations
,
January 2024 in “Frontiers in Pharmacology” These migraine prevention drugs can cause side effects like constipation, hair loss, injection site reactions, fatigue, and sometimes unexpected issues like Raynaud's phenomenon and weight gain.
14 citations
,
June 2021 in “British Journal of Dermatology” The BIOMAP glossary standardizes data to improve research on atopic dermatitis and psoriasis.
July 2025 in “Journal of Investigative Dermatology” Breezula® may be more effective than Minoxidil in promoting hair growth by reducing a hair growth inhibitor.
9 citations
,
May 2022 in “Drugs in Context” Sonidegib effectively treated advanced basal cell carcinoma with mild side effects.
January 2025 in “Repository of the Academy's Library (Library of the Hungarian Academy of Sciences)” Baricitinib is effective and safe for treating severe alopecia areata.
September 2025 in “International Journal of Molecular Sciences” Deucravacitinib may help treat various immune diseases beyond psoriasis, but more research is needed.
August 2018 in “Journal of The American Academy of Dermatology” Different treatments for skin conditions were found to be effective and generally safe, with biologics recommended as the first choice for generalized pustular psoriasis.
4 citations
,
June 2013 in “The Journal of Rheumatology” The document concludes that various findings in rheumatology offer insights into disease severity, treatment responses, and potential risks in medication, with some limitations due to unspecified participant numbers.
1 citations
,
September 2025 in “Plant Science Today” The herbal mix of hibiscus and vitex shows promise for treating autoimmune diseases due to its effectiveness and low toxicity.
20 citations
,
May 2007 in “JDDG Journal der Deutschen Dermatologischen Gesellschaft” Etanercept effectively treated a severe skin condition when other treatments failed.
1 citations
,
August 2021 in “Journal of The American Academy of Dermatology” Baricitinib helped improve hair, eyebrow, and eyelash growth in alopecia areata patients.
April 2023 in “Journal of Investigative Dermatology” CD8+ T cells attack hair follicle stem cells, causing scarring and hair loss.
355 citations
,
January 2017 in “Journal of the American Academy of Dermatology” JAK inhibitors show promise for treating skin conditions like eczema, hair loss, and psoriasis.
July 2025 in “Clinical Dermatology Review” Azathioprine can cause unexpected hair loss and severe bone marrow issues, so careful monitoring is needed.
90 citations
,
January 1989 in “PubMed” 8 citations
,
February 2006 in “Canadian Medical Association Journal” A woman with lupus and antiphospholipid syndrome had bone damage, showing the need for careful treatment.
March 2026 in “Immunological Medicine” Janus kinase inhibitors help some people with severe alopecia areata regrow hair, but not everyone responds, and relapses can happen.
January 2018 in “Practical diabetes” Leflunomide is effective for rheumatoid arthritis but has significant side effects.
54 citations
,
February 1994 in “Journal of Investigative Dermatology” June 2020 in “Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature” Researchers found a specific T cell receptor linked to severe drug reactions like Stevens-Johnson syndrome when patients take carbamazepine.
January 2025 in “Archives of Dermatological Research”
Deuruxolitinib is approved to treat severe alopecia areata in adults.
April 2023 in “Journal of Investigative Dermatology” Baricitinib at 2mg and 4mg doses improved work productivity and reduced costs for adults with atopic dermatitis.
20 citations
,
December 2021 in “Journal of the American Academy of Dermatology” Continuous treatment with ritlecitinib and brepocitinib is needed to maintain hair regrowth in alopecia areata.
June 2017 in “Poster presentations” All four treatments for early rheumatoid arthritis had similar safety profiles.